2023
PO83 Utilization of a Virtual Clinical Trial to Characterize Sensitivity of the Linear-Quadratic Model
Tien C, Draeger E, Guan F, Carlson D, Chen Z. PO83 Utilization of a Virtual Clinical Trial to Characterize Sensitivity of the Linear-Quadratic Model. Brachytherapy 2023, 22: s110. DOI: 10.1016/j.brachy.2023.06.184.Peer-Reviewed Original ResearchTumor control probabilityClinical trialsLinear-quadratic modelNumber of patientsPatient cohort sizeTCP curvesRadiobiological parametersVirtual clinical trialsGy-1Cohort sizeRange of dosesPatient outcomesReference cohortPatientsHeterogeneous cohortVirtual patientsNew trialsRadiobiological parameter valuesClonogenic populationPatient ordersControl probabilityGyInput model parametersTrialsCohort
2017
Stage I Lung SBRT Clinical Practice Patterns
Corso CD, Park HS, Moreno AC, Kim AW, Yu JB, Husain ZA, Decker RH. Stage I Lung SBRT Clinical Practice Patterns. American Journal Of Clinical Oncology 2017, 40: 358-361. PMID: 25503436, DOI: 10.1097/coc.0000000000000162.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyNational Cancer DatabaseStage I non-small cell lung cancer patientsUse of SBRTNon-small cell lung cancer patientsCell lung cancer patientsStage I NSCLCMajority of patientsClinical practice patternsLung cancer patientsBody radiation therapyMedian BED10SBRT useDosing guidelinesRetrospective studyCancer patientsPrescription trendsCancer DatabasePractice patternsRadiation therapyPatientsDose prescriptionGyRegimensCommon prescription
2016
A Biologically Effective Dose of ≥105 Gy Is Associated With Improved Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy
Stahl J, Ross R, Harder E, Mancini B, Soulos P, Dosoretz A, Finkelstein S, Shafman T, Husain Z, Evans S, Yu J, Gross C, Decker R. A Biologically Effective Dose of ≥105 Gy Is Associated With Improved Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2016, 96: s174-s175. DOI: 10.1016/j.ijrobp.2016.06.438.Peer-Reviewed Original Research
2015
Adjuvant hypofractionated partial-brain radiation therapy for pediatric Ewing sarcoma brain metastases: case report.
van Dams R, Park HS, Alomari AK, Ricciardi AS, Rao H, McNamara J, DiLuna ML, Bindra RS. Adjuvant hypofractionated partial-brain radiation therapy for pediatric Ewing sarcoma brain metastases: case report. Journal Of Neurosurgery Pediatrics 2015, 17: 434-8. PMID: 26636250, DOI: 10.3171/2015.8.peds15313.Peer-Reviewed Original ResearchConceptsPartial brain radiation therapyRadiation therapyCase reportSarcoma brain metastasesEvidence of diseaseGross tumor resectionGross total resectionBrain metastasesInflammatory changesIntracranial metastasesSarcoma metastasisTumor resectionMetastasisTherapyResectionPatientsLimited marginReasonable approachReportDexamethasoneDiseaseGyBrainMonthsSU‐E‐T‐787: Utility of the Two Candidate 192‐Ir and 169‐Yb HDR Sources for Use with a Novel Direction Modulated Brachytherapy Tandem Applicator for Cervical Cancer Treatment
Safigholi H, Han D, Soliman A, Meigooni A, Song W. SU‐E‐T‐787: Utility of the Two Candidate 192‐Ir and 169‐Yb HDR Sources for Use with a Novel Direction Modulated Brachytherapy Tandem Applicator for Cervical Cancer Treatment. Medical Physics 2015, 42: 3518-3518. DOI: 10.1118/1.4925151.Peer-Reviewed Original ResearchDirection modulated brachytherapyHDR sourceYb-169Ir-192Treatment planning programTG-43Dose matrixTungsten alloysConformal plansPrescription doseHR-CTVTandem applicationsHRCTV D90Ring-planeIntensity modulationCervical cancer treatmentGyV100Cancer treatmentClinical casesOARsEvaluate treatmentDirectional beamsD2ccD98SU‐C‐BRD‐05: Non‐Invasive in Vivo Biodosimetry in Radiotherapy Patients Using Electron Paramagnetic Resonance (EPR) Spectroscopy
Bahar N, Roberts K, Stabile F, Mongillo N, Decker R, Wilson L, Husain Z, Contessa J, Williams B, Flood, Swartz H, Carlson D. SU‐C‐BRD‐05: Non‐Invasive in Vivo Biodosimetry in Radiotherapy Patients Using Electron Paramagnetic Resonance (EPR) Spectroscopy. Medical Physics 2015, 42: 3192-3193. DOI: 10.1118/1.4923800.Peer-Reviewed Original ResearchTotal body irradiationRadiotherapy patientsRadiation doseNeck radiotherapy patientsUpper central incisorsBiomedical Advanced ResearchBody irradiationFree radicalsFirst treatmentMedical interventionsEfficient triageCentral incisorsMedical countermeasuresPatientsDoseGyPreliminary dataHuman dataRetrospective biodosimetrySubsequent fractionsHuman ServicesInterventionLuminescent dosimetersMagnetic resonancePilot program
2013
Dosimetric and clinical predictors of the development of moist desquamation in breast cancer irradiation
Rutter C, Qin L, Higgins S, Moran M, Evans S. Dosimetric and clinical predictors of the development of moist desquamation in breast cancer irradiation. Journal Of Radiation Oncology 2013, 3: 147-152. DOI: 10.1007/s13566-013-0129-0.Peer-Reviewed Original ResearchMoist desquamationWhole breast radiotherapyAdjuvant whole breast radiotherapyLogistic regressionResultsTwenty-three patientsBreast cancer irradiationKaplan-Meier analysisImpact of patientLog-rank testMultivariate logistic regressionSignificant predictorsDose-volume relationshipClinical predictorsConsecutive patientsPatient factorsBreast radiotherapyGy fractionsCancer irradiationPatientsRadiotherapyBMIBreastTreatment factorsGyDesquamation
2011
Phase I/II trial of bevacizumab (B) and erlotinib (E) with induction (IND) and concurrent (CON) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic conformal radiotherapy (TCRT) in stage III non-small cell lung cancer (NSCLC).
Stinchcombe T, Socinski M, Moore D, Gettinger S, Decker R, Petty W, Blackstock A, Schwartz G, Lankford S, Morris D. Phase I/II trial of bevacizumab (B) and erlotinib (E) with induction (IND) and concurrent (CON) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic conformal radiotherapy (TCRT) in stage III non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2011, 29: 7016-7016. DOI: 10.1200/jco.2011.29.15_suppl.7016.Peer-Reviewed Original Research
2010
Impact of Dose on Local Failure Rates After Image-Guided Reirradiation of Recurrent Paraspinal Metastases
Damast S, Wright J, Bilsky M, Hsu M, Zhang Z, Lovelock M, Cox B, Zatcky J, Yamada Y. Impact of Dose on Local Failure Rates After Image-Guided Reirradiation of Recurrent Paraspinal Metastases. International Journal Of Radiation Oncology • Biology • Physics 2010, 81: 819-826. PMID: 20888133, DOI: 10.1016/j.ijrobp.2010.06.013.Peer-Reviewed Original ResearchConceptsImage-guided intensity-modulated radiotherapyLocal failure rateParaspinal metastasisImpact of doseDaily fractionsIncidence of myelopathySingle-fraction regimensRecords of patientsRisk of myelopathyIntensity-modulated radiotherapyCumulative incidenceEpidural diseaseField recurrenceDose groupProspective dataFailure rateTreatment characteristicsLF incidenceMetastasisIncidenceSignificant decreaseGyMyelopathyDoseIg
2004
Relation of clinical success in coronary brachytherapy to dose
Singh HS, Yue N, Azimi N, Nath R, Roberts KB, Pfau S. Relation of clinical success in coronary brachytherapy to dose. The American Journal Of Cardiology 2004, 94: 847-852. PMID: 15464663, DOI: 10.1016/j.amjcard.2004.06.016.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBrachytherapyCase-Control StudiesConnecticutCoronary AngiographyCoronary RestenosisCoronary VesselsDose-Response Relationship, RadiationFemaleFollow-Up StudiesHumansMaleMiddle AgedMultivariate AnalysisRadiotherapy DosageRetrospective StudiesStatistics as TopicTreatment OutcomeUltrasonography, InterventionalConceptsTreatment failureExternal elastic membraneTreatment successStent restenosisIntravascular ultrasoundAdequate dose deliveryRecurrent restenosisLesion patternsPrimary treatmentCoronary brachytherapyClinical successPatientsDose prescriptionRadiation delivery systemsArteryRestenosisGyDoseBrachytherapyDose thresholdRadiation delivery devicePotential causesDose deliveryIntravascular brachytherapyTreatment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply